News-Medical.Net on MSN7h
Exploring the therapeutic potential of flavonoids in type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...
Physician's Weekly2h
GLP-1 Receptor Agonists and Hematologic Cancer Risk in Type 2 Diabetes
The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...
Medscape1d
Automated Insulin Delivery System Helps in Type 2 Diabetes
The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...
Crain's Chicago Business1d
Xeris enters a whole new market for one of its main pharma offerings
Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...
5 Ways To Balance Glucose For More Energy, According to a Nutritionist
According to nutritionist Ángela Quintas it all comes down to what you’re eating—and, more specifically, how it impacts your ...
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...
Weight-loss drug Mounjaro in India: Is it better than Ozempic?
US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...
Mounrjaro hits shelves in India: How Eli Lilly’s anti-diabetes drug compares with Ozempic — price, side effects and more
Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...